Eurizon Capital SGR S.p.A. cut its position in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 57.8% during the undefined quarter, according to the company in its most recent filing with the SEC. The firm owned 108,181 shares of the biopharmaceutical company's stock after selling 148,455 shares during the quarter. Eurizon Capital SGR
Alps Advisors Inc. trimmed its stake in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 98.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,608 shares of the biopharmaceutical company's stock after selling 310,727 shares during the period. Alps Advisors Inc.'s
NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference on Tuesday, November 17, 2026 at 5:40 a.m. ET / 10:40 a.m. GMT.
Royalty Pharma's Q3 royalty receipts increased 9% to $883 million, led by strong growth in Tremfya, Voranigo, and Evrysdi. Vertex now accounts for approximately 25% of royalty receipts, indicating that newer medicines are gradually reducing the portfolio's concentration. Management raised its 2026 guidance again, while new drug approvals, additional investments, and share buybacks support future growth.
Biotech usually torches cash and dilutes shareholders to fund the next trial. Three drugmakers flip that script, and the one with the smallest yield may be hiding the sturdiest payout of all.
Royalty Pharma plc is the global leader in acquiring biopharmaceutical royalties, offering investors exposure to blockbuster therapies and megatrend-driven growth. RPRX focuses on de-risked, post-proof-of-concept assets, delivering attractive risk-adjusted returns with a return on invested capital around 15% and equity returns near 21%. The business model is defensive, uncorrelated with macro trends, and benefits from scale, high operating margins, and expert capital allocation.